Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on November 24 backed approval for MSD’s immune checkpoint inhibitor Keytruda (pembrolizumab) for the treatment of PD-L1-positive unresectable, advanced or relapsed non-small cell lung cancer (NSCLC) both…
To read the full story
Related Article
- MHLW OKs Tecfidera, Otezla, Other Drugs
December 20, 2016
- Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings
December 20, 2016
- MHLW Panel OKs Celgene’s Apremilast, 2 Other NMEs
November 25, 2016
REGULATORY
- MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
November 20, 2026
- Mumps Shots Gain Strong Backing as Japan Weighs FY2027 NIP Priorities
November 20, 2026
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026





